Apr 15, 2025 7:00 am EDT MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)
Mar 06, 2025 7:00 am EST MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
Feb 20, 2025 7:00 am EST MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
Feb 04, 2025 7:00 am EST MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Jan 30, 2025 7:00 am EST MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder